VivoSim Labs, Inc. (NASDAQ: VIVS) has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds through a private placement, the company announced. The transaction involves the sale of 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants at a combined price of $0.85 per share. The warrants, exercisable following shareholder approval, have a five-year term from the initial exercise date and an exercise price of $0.85 per share. Additionally, subject to shareholder approval, the company has agreed to amend certain existing warrants issued in May 2024 by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, pending customary closing conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction.
This capital infusion comes at a time when VivoSim is positioning itself as a key player in the shift toward non-animal testing methods. The company focuses on providing testing of drugs and drug candidates using three-dimensional human tissue models of the liver and intestine. These new approach methodologies (NAMs) are gaining traction following the U.S. Food and Drug Administration's roadmap to refine animal testing requirements in favor of these non-animal methods. VivoSim anticipates accelerated adoption of its human tissue models as regulatory and industry trends move away from traditional animal testing.
The private placement underscores investor confidence in VivoSim's business model and the broader market potential for NAMs. By securing funding from a healthcare-focused institutional investor, the company gains not only capital but also strategic alignment with a partner knowledgeable in the life sciences sector. The reduction of the exercise price on existing warrants may also signal alignment of interests between the company and its investors, potentially encouraging future conversion and reducing dilution over time.
VivoSim Labs, based in San Diego, California, operates as a pharmaceutical and biotechnology services company. The company offers partners liver and intestinal toxicology insights using its NAM models, which could reduce reliance on animal testing and provide more human-relevant data. As regulatory bodies and pharmaceutical companies increasingly seek alternatives to animal models, VivoSim's services may see growing demand.
This announcement follows the company's earlier efforts to advance its technology and business development. The proceeds from the private placement are expected to support ongoing operations, research and development, and general corporate activities. For more information about VivoSim Labs, visit the company's website at https://vivosim.ai/. The full press release is available at https://ibn.fm/7Ov0B.
